Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Similar documents
Out-Patient Billing CPT Codes

The Center for PERSONALIZED DIAGNOSTICS

NeoTYPE Cancer Profiles

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

August 17, Dear Valued Client:

Genomic Medicine: What every pathologist needs to know

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

NeoTYPE Cancer Profiles

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Accel-Amplicon Panels

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Molecular Genetic Testing for the Diagnosis of Haematological Malignancies

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

ADRL Advanced Diagnostics Research Laboratory

West Midlands Regional Genetics Laboratory

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

EBUS-TBNA Diagnosis and Staging of Lung Cancer

Illumina s Cancer Research Portfolio and Dedicated Workflows

molecular oncology services

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders

Oxford BRC Haemato-Molecular Diagnostic Service

Clinical Grade Genomic Profiling: The Time Has Come

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Next generation histopathological diagnosis for precision medicine in solid cancers

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Detecting Oncogenic Mutations in Whole Blood

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)

Diagnostica Molecolare!

Please Silence Your Cell Phones. Thank You

Role of FISH in Hematological Cancers

School of Pathology and Laboratory Medicine: Current and New Research Interests

Your single-source laboratory solution. FISH Probe Library

Diagnostic application of SNParrays to brain cancers

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Precision Oncology: Experience at UW

Overview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

What is the status of the technologies of "precision medicine?

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Current Techniques in Molecular Biology Friedel Nollet, Ph.D.

Click to edit Master /tle style

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

Test Name Results Units Bio. Ref. Interval. Positive

Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz

Initial Diagnostic Workup of Acute Leukemia

Test Name Results Units Bio. Ref. Interval. Positive

Methods used to diagnose lymphomas

Oncology Cytogenetics Diagnostic Service - User Guide 2014

Molecular Diagnosis. Nucleic acid based testing in Oncology

Laboratory Service Report

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

The development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Molecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang

Oncology Genetics: Cytogenetics and FISH 17/09/2014

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

SESSION 1 Reactive cytopenia and dysplasia

Best of ASCO 2014 Sarcoma

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Clinical, Pathologic and Molecular Updates

HSL-Advanced Diagnostics 2018 / 19 Test & Service List

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

Plasma-Seq conducted with blood from male individuals without cancer.

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine

Liquid biopsy: the experience of real life case studies

Prior Authorization Required: Additional Information:

Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA

EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)

Molecular Advances in Hematopathology

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms

A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis

MOLECULAR SERVICES. mlabs.umich.edu

The Next Generation in Cancer Diagnostics.

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Pediatric Oncology & Pathology Services

Secuenciación masiva: papel en la toma de decisiones

HEMATOPATHOLOGY SUMMARY REPORT RL;MMR;

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms

Transcription:

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Haematopathology and Oncology Diagnostic Services (HODS) Addenbrookes Hospital Hills Road Cambridge CB2 0QQ Contact: Brian Warner Tel: +44 (0)1223 216745 E-Mail: brian.warner@addenbrookes.nhs.uk Website: www.cuh.org.uk Testing performed at the above address only DETAIL OF ACCREDITATION FLUIDS Blood, bone marrow, body fluid and human tissue (fresh, frozen or fixed) Formalin fixed parraffin embedded tissue Blood, bone marrow, body fluid and human tissue (fresh, frozen or fixed) Molecular Genetics activities for the purpose of clinical diagnosis DNA extraction using QIACube and SOP ADD-Mol.Mal 1015 Extraction of DNA deom Q-AL Lysis buffer using the Qiacube. FFPE Tissue DNA extraction using a manual process and SOP ADD- Mol.Mal 1095 DNA extraction from formalin fixed and paraffin embedded tissue. RNA extraction and preparation of cdna using QIACube and PTC-200 DNA engine MJ-Research (Biorad) thermal cycler and SOP ADD- Mol.Mal 0001 Extraction of RNA from RLT buffer using the QIACube. ADD-Mol.Mal 32382: Conversion of RNA to cdna by reverse transcription ADD-Mol.Mal 32278: Thermal Cyclers ADD-Mol.Mal 32054:BCR RT-PCR amplification for quality control of RNA extraction and cdna synthesis ADD-Mol.Mal 32184:Use of Gel Doc imager Assessment Manager: VB Page 1 of 22

FLUIDS Human Nucleic acid obtained from: A. DNA extracted from blood, bone marrow, body fluid and human tissue (fresh, frozen or fixed) B. cdna derived from RNA extracted from blood, bone marrow, body fluid and human tissue (fresh, frozen or fixed) Molecular Genetics activities for the purpose of clinical diagnosis Technique -6 & 9 Sequencing data derived externally Using the following technique/equipment : 1. Real time PCR using Applied Biosystems Realtime 7500 real time analyser 2. High resolution melt analysis using Rotorgene 6000 series QIAgen 3. Real time PCR using Rotorgene 6000 series - QIAgen 4. PCR detection of gene rearrangements using Thermal cyclers (PTC-200) DNA engine MJ-Research (Biorad) DNA Engine Peltier Thermal cycler (Biorad), Thermo PCR cycler (Fisher Scientific) MJ Research PCR cycler (Biorad), G Storm PCR Cycler (G Storm) 5. Fragment analysis with Beckman CEQ 8000 6. Fragment analysis with ABI3130/3730 (External testing) 7. Pyrosequencing of Bisulphite modified DNA using the Pyromark Q24 Pyrosequencer 8. Next generation sequencing using Ion Torrent One touch TM2 instrument, Ion Torrent One Touch TM ES Ion, Ion Torrent PGM System 9. Sanger sequencing with ABI3130/3730 (External testing) Assessment Manager: VB Page 2 of 22

FLUIDS Human Nucleic acid obtained from: A. DNA extracted from blood, bone marrow, body fluid and human tissue (fresh, frozen or fixed) B. cdna derived from RNA extracted from blood, bone marrow, body fluid and human tissue (fresh, frozen or fixed) See above Molecular Genetics activities for the purpose of clinical diagnosis Using the following technique/equipment : 10. Heteroduplex treatment and polyacrylamide gel electrophoresis of PCR products (ADD-Mol.Mal 32010) 11. Agarose Gel electrophoresis of PCR products (ADD- Mol.Mal 32055) 12. Gel Documentation System using Syngene Genius Bioimaging System and Agilent 4200TapeStation A JAK2 V617F Mutation Technique - 1 B BCR-ABL 1 Quantification Technique - 1 A BRAF V600-FFPE Technique - 2 ADD-Mol.Mal 32173 Real time PCR for the detection of the JAK2 V617F Mutation in myeloprofliferative neoplasms ADD.Mol.Mal 32303 Real Time PCR for the quantification of E13A2 or E14A2 BCR-ABL fusion transcripts ADD-Mol.Mal 1882 Detection of BRAF V600 mutations in FFPE specimens by PCR and HRM analysis Assessment Manager: VB Page 3 of 22

FLUIDS See above Molecular Genetics activities for the purpose of clinical diagnosis A NPM1 exon 12 mutation Technique - 2 A MPL exon 10 mutation Technique - 2 A JAK2 exon 12 mutation Technique - 2 A BRAF exon 15 mutations Technique - 2 A KRAS codons 12 and 13 Technique - 2 A KIT D816V Mutation Technique - 3 B FIP1L1-PDGFRA Fusion gene Technique - 3 ADD-Mol.Mal 1919 Melting curve analysis for the detection of NPM1 exon 12 mutations ADD-Mol.Mal 32053 Melting curve analysis for the detection of mutations within MPL exon 10 ADD-Mol.Mal 32067 Melting curve analysis for the detection of mutations within JAK2 exon 12 ADD Mol.Mal 340 HRM method for detection of BRAF exon 15 mutations: Fresh material protocol. ADD-Mol.Mal 95229 Detection of KRAS codon 12 and 13 mutations by PCR and high resolution melting analysis ADD-Mol.Mal 1568 Real time PCR for the detection of the KIT D816V Mutation ADD-Mol.Mal 811 Real time PCR for the detection of the FIP1L1- PDGFRA Fusion transcript Assessment Manager: VB Page 4 of 22

FLUIDS See above Molecular Genetics activities for the purpose of clinical diagnosis B NPM-ALK fusion gene Technique - 3 A MYD88 L265P Mutation Technique - 3 ADD-Mol.Mal 550 Real time PCR for the detection of the NPM-ALK fusion transcript ADD-Mol.Mal 95250 Real time PCR for the detection of the MYD88 L265P Mutation in lymphoblastic lymphoma A Externally generated DNA sequence data from sample/pcr products as above A Externally generated DNA sequence data from sample/pcr products as above Production of PCR products for the purposes of external sequencing IG Gene rearrangements Production of PCR products for the purposes of external sequencing TCR Gene rearrangements Technique 4, (6), 10, 11, 12 ADD-Mol.Mal 32224: PCR analysis of immunoglobulin (IG) gene rearrangements to demonstrate clonality ADD-Mol.Mal 31996: B cell and T cell clonality analysis in suspect lymphoproliferations using FFPE tissue Technique 4, (6), 10, 11, 12 ADD-Mol.Mal 32222: PCR analysis of T cell receptors (TCR) gene rearrangements to demonstrate clonality ADD-Mol.Mal 31996: B cell and T cell clonality analysis in suspect lymphoproliferations using FFPE tissue Assessment Manager: VB Page 5 of 22

FLUIDS See above Molecular Genetics activities for the purpose of clinical diagnosis A Chimerism analysis Technique 4, 5 ADD-Mol.Mal 95242: Chimerism 1:Lineage specific cell extraction from peripheral blood ADD-Mol.Mal 95244: Chimerism 3:Data interpretation A Genotyping Technique 4, 5 HODS.SOP.MOL.02214 STR (Short tandem repeat) genotyping by PCR and genescan for tissue identity testing ADD-Mol.Mal 95244: Chimerism 3:Data interpretation A CALR Exon 9 mutation analysis Technique 4, 5 ADD-Mol.Mal 2486:PCR and fragment analysis for the detection of mutations within CALR exon 9 A Externally generated DNA sequence data from sample/pcr products as above Production of PCR products for the purposes of external sequencing Microsatellite analysis Technique 6 sequencing data derived externally Technique 4, (6) ADD-Mol.Mal 2357: Detection of microsatellite instability by: PCR and fragment analysis for screening of Lynch Syndrome A MGMT Promoter methylation Technique 4, 7 ADD-Mol.Mal 2718: Bisulphite modification of DNA for assessment of MGMT methylation status ADD-Mol.Mal 2723:PCR and pyrosequencing of Bisuplhite modified DNA for the analysis of MGMT promoter methylation Assessment Manager: VB Page 6 of 22

FLUIDS See above A A Molecular Genetics activities for the purpose of clinical diagnosis Cancer hot spot panel for the detection of gene presence, mutations and deletions (ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CTNNB1, CSF1R, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, JAK2, JAK3, IDH2, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL) Targeted Myeloid gene panel for the detection of gene presence, mutations and deletions (ASXL1, BRAF, CBL, CEBPA, DNMT3A, FLT3, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2, TP53, WT1, SF3B1, SRSF2) Technique 8 HODS.SOP.MOL.03251 Next Generation Sequencing 1: Preparation of DNA library using the Cancer Hotspot Panel v2 HODS.SOP.MOL.03252 Next Generation Sequencing 2: Amplification & Quantification of Patient specific libraries HODS.SOP.MOL.03258 Next Generation Sequencing 3: Using Ion Chef TM System for Emulsion PCR, Enrichment of Patient Libraries and Loading ISPs onto Chips HODS.SOP.MOL.03259 Next Generation Sequencing: Preparation of DNA library using the Custom Ampliseq Myeloid Panel HODS.SOP.MOL.03260 Next Generation Sequencing: Purification and Quantification of Patient specific libraries of Custom Myeloid Panel HODS.MOL.03253 Next Generation Sequencing: Using the Ion One Touch-2 Instrument to prepare Template Positive Ion Sphere Particles (ISPs). HODS.MOL.03254 Next Generation Sequencing: Initialization and Setting up the ION PGM System for sequencing Patient Libraries Assessment Manager: VB Page 7 of 22

FLUIDS See above A A B Externally generated DNA sequence data from sample/pcr products as above A Externally generated DNA sequence data from sample/pcr products as above Molecular Genetics activities for the purpose of clinical diagnosis Cancer hot spot panel for the detection of gene presence, mutations and deletions (ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CTNNB1, CSF1R, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, JAK2, JAK3, IDH2, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL) Targeted Myeloid gene panel for the detection of gene presence, mutations and deletions (ASXL1, BRAF, CBL, CEBPA, DNMT3A, FLT3, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2, TP53, WT1, SF3B1, SRSF2) Production of PCR products for the purposes of external sequencing BCR-ABL1 Kinase domain Production of PCR products for the purposes of external sequencing NRAS exons 2/3 HODS.MOL.03255 Next Generation Sequencing: Sequencing Protocol using the Ion 316 Chip v2 or Ion 318 Chip v2 HODS.MOL.03256 Next Generation Sequencing: Cleaning & Maintenance of the Ion Personal Genome Machine (PGM ) HODS.MOL.03257 Next Generation Sequencing: Data Assessment, Analysis, Annotation and Reporting using the Torrent Suite Software and Ion Reporter Software HODS.MOL.03356 Next Generation Sequencing: Enrichment of Template Positive Ion Sphere Particles (ISPs) using the Ion OneTouch ES Technique 4, (9), 11, 12 ADD-Mol.Mal 2489 BCR-ABL1 Kinase domain mutation analysis Technique 3, 4, (6) ADD-Mol.Mal 2538:PCR and sequence analysis for the detection of mutations within the NRAS exons 2 or 3 Assessment Manager: VB Page 8 of 22

FLUIDS See above A Externally generated DNA sequence data from sample/pcr products as above A Externally generated DNA sequence data from sample/pcr products as above A and B Externally generated DNA sequence data from sample/pcr products as above Molecular Genetics activities for the purpose of clinical diagnosis Production of PCR products for the purposes of external sequencing KRAS exons ¾ Production of PCR products for the purposes of external sequencing EGFR Production of PCR products for the purposes of external sequencing IGHV Mutation status Technique 9 - sequencing data derived externally Technique 3, 4, (6) ADD-Mol.Mal 2538:PCR and sequence analysis for the detection of mutations within the KRAS exons 3 or 4 Technique 3, 4, (6) AA-Mol.Mal 257: Detection of EGFR mutations by PCR and sequencing Technique 4, (9), 11, 12 HODS.SOP.MML95247 Multiplex PCR for the determination of mutation status of the IGHV locus B PML-RARA (Diagnosis) Technique 4, 11, 12 ADD-Mol.Mal 32181: RT-PCR for the detection of PML-RARA fusion transcripts B MOZ-CBP Technique 4, 11, 12 ADD-Mol.Mal 32132: RT-PCR detection of MOZ-CBP [t(8;16)(p11;p13) B BCR-ABL1 (Diagnosis) Technique 4, 11, 12 ADD-Mol.Mal 32139:RT-PCR for the detection of BCR-ABL fusion transcripts Assessment Manager: VB Page 9 of 22

FLUIDS See above Molecular Genetics activities for the purpose of clinical diagnosis B AML-ETO (Diagnosis) Technique 4, 11, 12 ADD-Mol.Mal 32247:RT-PCR for the detection of AML1-ETO fusion transcripts B CBFB-MTH11 (Diagnosis) Technique 4, 11, 12 ADD-Mol.Mal 32254:RT-PCR for the detection of CBFB-MYH11 fusion transcripts B E2A-PBX1 (Diagnosis) Technique 4, 11, 12 ADD-Mol.Mal 32268:RT-PCR for the detection of E2A-PBX1 fusion transcripts B MLL-x Technique 4, 11, 12 ADD-Mol.Mal 32270:RT-PCR for the detection of MLL-X fusion transcripts B TEL-AML1 (Diagnosis) Technique 4, 11, 12 ADD-Mol.Mal 32272:RT-PCR for the detection of TEL-AML1 fusion transcripts B FIP1L1-PDGFRA Technique 4, 11, 12 ADD-Mol.Mal 32287:Nested RT- PCR for the detection of the FIP1L1-PDGFRA Assessment Manager: VB Page 10 of 22

FLUIDS Blood, Bone marrow, CSF, Biopsy material, body fluids and FFPE tissue CYTOGENETIC analysis for detection of chromosomal aberrations in the diagnosis of Haematological malignancy. FISH analysis using fluorescent labelled gene probes and fluorescence microscopy to detect chromosome structural rearrangements and copy number of specific regions of the genome 1p36 13q14.3 19q13 17p TP53 ALK AP12-MALT1 ATM ATM/CEP11 BCL2 BCL6 BCR-ABL1 TRIPLE BCR-ABL1 CBFB CBFB/MYH11 CCND1 CDKN2A/CEP9 Tissue culture and harvest using the following SOPs ADD Hae 16301 Preparation of sample transport medium bottles ADD Hae 32022 Estimating White cell counts ADD Hae 16279 one marrow culture-setting up (Slanted culture ADD Hae 16277 Bone marrow culture:harvest (slanted culture SOP ADD Hae 16290: Standard technical procedure Cytogenetic analysis using Fluorescence in situ hybridisation (FISH) SOPs ADD Hae 16289 (FISH) ADD-Mol Mal.32482: Use of pressure cooker for pre-treatment of paraffin sections for interphase FISH ADD Hae 32138 Paraffin embedded tissue (PET) FISH Assessment Manager: VB Page 11 of 22

FLUIDS Blood, Bone marrow, CSF, Biopsy material, body fluids and FFPE tissue CYTOGENETIC analysis for detection of chromosomal aberrations in the diagnosis of Haematological malignancy. FISH analysis using fluorescent labelled gene probes and fluorescence microscopy to detect chromosome structural rearrangements and copy number of specific regions of the genome CEP1 CEP2 CEP3 CEP4 CEP6 CEP7 CEP8 CEP9 CEP10 CEP11 CEP12 CEP15 CEP16 CEP17 CEP18 CEP20 Tissue culture and harvest using the following SOPs ADD Hae 16301 Preparation of sample transport medium bottles ADD Hae 32022 Estimating White cell counts ADD Hae 16279 one marrow culture-setting up (Slanted culture ADD Hae 16277 Bone marrow culture:harvest (slanted culture SOP ADD Hae 16290: Standard technical procedure Cytogenetic analysis using Fluorescence in situ hybridisation (FISH) SOPs ADD Hae 16289 (FISH) ADD-Mol Mal.32482: Use of pressure cooker for pre-treatment of paraffin sections for interphase FISH ADD Hae 32138 Paraffin embedded tissue (PET) FISH Assessment Manager: VB Page 12 of 22

FLUIDS Blood, Bone marrow, CSF, Biopsy material, body fluids and FFPE tissue CYTOGENETIC analysis for detection of chromosomal aberrations in the diagnosis of Haematological malignancy. FISH analysis using fluorescent labelled gene probes and fluorescence microscopy to detect chromosome structural rearrangements and copy number of specific regions of the genome CEP XY CKS1B/CDKN2C D20S108 D7S522/CEP7 DEK/NUP214 EGR1/D5S23 EML4-ALK ETV6 ETV6/RUNX1 EV11 (MECOM) EWSR1 FGFR1 FIPIL1/PDGFRA FOX01 IGH IGH/MAF Tissue culture and harvest using the following SOPs ADD Hae 16301 Preparation of sample transport medium bottles ADD Hae 32022 Estimating White cell counts ADD Hae 16279 one marrow culture-setting up (Slanted culture ADD Hae 16277 Bone marrow culture:harvest (slanted culture SOP ADD Hae 16290: Standard technical procedure Cytogenetic analysis using Fluorescence in situ hybridisation (FISH) SOPs ADD Hae 16289 (FISH) ADD-Mol Mal.32482: Use of pressure cooker for pre-treatment of paraffin sections for interphase FISH ADD Hae 32138 Paraffin embedded tissue (PET) FISH Assessment Manager: VB Page 13 of 22

FLUIDS Blood, Bone marrow, CSF, Biopsy material, body fluids and FFPE tissue CYTOGENETIC analysis for detection of chromosomal aberrations in the diagnosis of Haematological malignancy. FISH analysis using fluorescent labelled gene probes and fluorescence microscopy to detect chromosome structural rearrangements and copy number of specific regions of the genome IGH-BCL2 IGH-CCND1 IGH-FGFR3 IGH-MALT1 IGH-MYC/CEP8 IGK IGL KIAA1549-BRAF MALT1 MDM2 MLL MYB/CEP6 MYC MYCN PAX3 PAX7 Tissue culture and harvest using the following SOPs ADD Hae 16301 Preparation of sample transport medium bottles ADD Hae 32022 Estimating White cell counts ADD Hae 16279 one marrow culture-setting up (Slanted culture ADD Hae 16277 Bone marrow culture:harvest (slanted culture SOP ADD Hae 16290: Standard technical procedure Cytogenetic analysis using Fluorescence in situ hybridisation (FISH) SOPs ADD Hae 16289 (FISH) ADD-Mol Mal.32482: Use of pressure cooker for pre-treatment of paraffin sections for interphase FISH ADD Hae 32138 Paraffin embedded tissue (PET) FISH Assessment Manager: VB Page 14 of 22

FLUIDS Blood, Bone marrow, CSF, Biopsy material, body fluids and FFPE tissue CYTOGENETIC analysis for detection of chromosomal aberrations in the diagnosis of Haematological malignancy. FISH analysis using fluorescent labelled gene probes and fluorescence microscopy to detect chromosome structural rearrangements and copy number of specific regions of the genome PDGFB PDGFRB PML/RARA RARA RUNX1/RUNX1T1 SS18 STIL/TAL1 TCF (E2A) TLX3 TOP2A TP53/CEP17 TRA/TRD TRB TRG Tissue culture and harvest using the following SOPs ADD Hae 16301 Preparation of sample transport medium bottles ADD Hae 32022 Estimating White cell counts ADD Hae 16279 one marrow culture-setting up (Slanted culture ADD Hae 16277 Bone marrow culture:harvest (slanted culture SOP ADD Hae 16290: Standard technical procedure Cytogenetic analysis using Fluorescence in situ hybridisation (FISH) SOPs ADD Hae 16289 (FISH) ADD-Mol Mal.32482: Use of pressure cooker for pre-treatment of paraffin sections for interphase FISH ADD Hae 32138 Paraffin embedded tissue (PET) FISH Assessment Manager: VB Page 15 of 22

FLUIDS Blood, bone marrow CYTOGENETIC analysis for detection of chromosomal aberrations in the diagnosis of Haematological malignancy G-Banded karyotype analysis for detection of chromosome abnormalities associated with haemato-oncology disorders. Tissue culture and harvest using the following SOPs ADD Hae 16301 Preparation of sample transport medium bottles ADD Hae 16303: Preparation of culture medium ADD Hae 32022 Estimating White cell counts ADD Hae 16279 one marrow culture-setting up (Slanted culture ADD Hae 16277 Bone marrow culture:harvest (slanted culture ADD Hae 16313:Slide making ADD Hae 16292: G-Banding SOP ADD Hae 2919 GenASIs manual G band Image capture ADD Hae 2308 GenaASIs metaphase automated scan and capture SOP ADD Hae 16284 G banded karyotype analysis Cytogenetic Report writing ADD Hae 16319 and issuing reports ADD Hae 16297 Issuing Cytogenetics reports Assessment Manager: VB Page 16 of 22

FLUIDS Blood, Bone marrow, CSF, biopsy material, FNA and body fluids Blood, bone marrow, CSF, Biopsy material, FNA s, body fluids Diagnosis and monitoring of haematological malignancy and bone marrow failure syndromes Morphological assessment and examination of fixed and unfixed stained human tissue/cells/fluid haematological cells to identify or exclude morphological and cytological abnormalities for the purpose of diagnosis and monitoring of a range of malignant and non-malignant haematological disorders. Immunophenotyping of the following markers/antigens to diagnose and monitor the following disorders: Hematek automated stainer using modified wrights stain and Shandon cytocentrifuge II ADD Hae 16403 Peripheral blood ADD Hae 16360 Bone marrow ADD Hae 16365 CSF ADD Hae 16406 Lymph node preparation ADD Hae 32280 Hematek slide stainer ADD.Hae 16389 Iron stain ADD Hae 16382 Haemosiderin ADD Hae 16396 Myeloperoxidase stain ADD Hae 995 Morphology review- Microscopy Flow cytometry 8 colour BDBioscience FACSCanto II flow cytometer ADD Hae 16403 Peripheral blood ADD Hae 16360 Bone marrow ADD Hae 16365 CSF ADD Hae 16406 Lymph Node Preparation ADD Hae 32262 Broncho alveolar lavage ADD Hae 32358 Nuclear and cytoplasmic staining ADD Hae 32450 DNA Index and with reference to the following specific SOPs Acute leukaemia ADD Hae 32357 Chronic leukaemia T and B lymphoproliferative ADD Hae 32362 B cell panel disorders ADD Hae 32438 T cell panel Plasma cell disorders ADD Hae 32360 Plasma cell panel Hairy Cell panel ADD Hae 32363 Hairy cell panel CD1a CD2 CD3 Assessment Manager: VB Page 17 of 22

FLUIDS Blood, bone marrow, CSF, Biopsy material, FNA s, body fluids Diagnosis and monitoring of haematological malignancy and bone marrow failure syndromes Immunophenotyping of the following markers/antigens to diagnose and monitor the following disorders: Flow cytometry 8 colour BDBioscience FACSCanto II flow cytometer ADD Hae 16403 Peripheral blood ADD Hae 16360 Bone marrow ADD Hae 16365 CSF ADD Hae 16406 Lymph Node Preparation ADD Hae 32262 Broncho alveolar lavage ADD Hae 32358 Nuclear and cytoplasmic staining ADD Hae 32450 DNA Index and with reference to the following specific SOPs Acute leukaemia ADD Hae 32357 Chronic leukaemia T and B lymphoproliferative ADD Hae 32362 B cell panel disorders ADD Hae 32438 T cell panel Plasma cell disorders ADD Hae 32360 Plasma cell panel Hairy Cell panel ADD Hae 32363 Hairy cell panel CD4 CD5 CD7 CD8 CD9 CD10 Assessment Manager: VB Page 18 of 22

FLUIDS Blood, bone marrow, CSF, Biopsy material, FNA s, body fluids Diagnosis and monitoring of haematological malignancy and bone marrow failure syndromes Immunophenotyping of the following markers/antigens to diagnose and monitor the following disorders : Acute leukaemia Chronic leukaemia T and B lymphoproliferative disorders Plasma cell disorders Hairy Cell panel CD11b CD11c CD13 CD14 CD15 CD16 CD19 CD20 CD22 CD23 CD24 CD25 CD33 CD34 CD36 CD38 CD41 CD42 CD43 CD45 CD52 CD56 CD57 CD61 Flow cytometry 8 colour BDBioscience FACSCanto II flow cytometer ADD Hae 16403 Peripheral blood ADD Hae 16360 Bone marrow ADD Hae 16365 CSF ADD Hae 16406 Lymph Node Preparation ADD Hae 32262 Broncho alveolar lavage ADD Hae 32358 Nuclear and cytoplasmic staining ADD Hae 32450 DNA Index and with reference to the following specific SOPs ADD Hae 32357 Acute Leukaemia ADD Hae 32362 B cell panel ADD Hae 32438 T cell panel ADD Hae 32360 Plasma cell panel ADD Hae 32363 Hairy cell panel Assessment Manager: VB Page 19 of 22

FLUIDS Blood, bone marrow, CSF, Biopsy material, FNA s, body fluids Diagnosis and monitoring of haematological malignancy and bone marrow failure syndromes Immunophenotyping of the following markers/antigens to diagnose and monitor the following disorders : Acute leukaemia Chronic leukaemia T and B lymphoproliferative disorders Plasma cell disorders Hairy Cell panel CD64 CD66b CD79a CD79b CD81 CD99 CD103 CD117 CD123 CD138 CD200 CD235a CD303 CD304 HLA-DR IgD IgG IgM Kappa Lambda NG-2 ROR1 TCR alpha/beta TCR gamma/delta Flow cytometry 8 colour BDBioscience FACSCanto II flow cytometer ADD Hae 16403 Peripheral blood ADD Hae 16360 Bone marrow ADD Hae 16365 CSF ADD Hae 16406 Lymph Node Preparation ADD Hae 32262 Broncho alveolar lavage ADD Hae 32358 Nuclear and cytoplasmic staining ADD Hae 32450 DNA Index and with reference to the following specific SOPs ADD Hae 32357 Acute Leukaemia ADD Hae 32362 B cell panel ADD Hae 32438 T cell panel ADD Hae 32360 Plasma cell panel ADD Hae 32363 Hairy cell panel Assessment Manager: VB Page 20 of 22

FLUIDS Blood, bone marrow Stem cell harvests (Cord blood, PB, BM) Diagnosis and monitoring of haematological malignancy and bone marrow failure syndromes CD34 +ve stem cell enumeration Flow cytometry 8 colour BD Bioscience FACSCanto II flow cytometer using SOPs ADD Hae 32455 Allogeneic cell harvests ADD Hae 1173 Single platform CD34 +ve cell enumeration ADD Hae 1004 Cord blood CD34 +ve cell enumeration Peripheral blood Immunological platelet enumeration Flow cytometry 8 colour BD Bioscience FACSCanto II flow cytometer using SOPs ADD Hae 32049 Immunological platelet count by flow cytometer (ICSH) Paroxysmal Nocturnal Haemoglobinuria (Red and white cells) FLAER CD14 CD24 CD33 CD64 CD66b CD59 CD235a Flow cytometry 8 colour BD Bioscience FACSCanto II flow cytometer using SOPs ADD Hae 32373 Paroxysmal Nocturnal Haemoglobinuria (PNH) diagnosis by flow cytometry of neutrophils (Canto II) ADD Hae 1463 Paroxysmal Nocturnal Haemoglobinuria (PNH) diagnosis by flow cytometry of red cells (Canto II) Assessment Manager: VB Page 21 of 22

FLUIDS Diagnosis and monitoring of haematological malignancy and bone marrow failure syndromes Peripheral blood Hereditary spherocytosis screening Esoin-5-Malemide binding assay flow cytometry using Flow cytometry 8 colour BD Bioscience FACSCanto II flow cytometer using SOPs ADD Hae 32444 Flow cytometry screening for Hereditary spherocytosis- Canto END Assessment Manager: VB Page 22 of 22